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PIC 024-4 and PRO 2000 are naphthalene sulfonate polymers that bind to CD4 with nanomolar affinity and
block binding of gp120. Both have activity against human immunodeficiency virus type 1 in H9 cells, peripheral
blood mononuclear cells, and primary monocyte/macrophages, are synergistic with zidovudine, and do not inhib-
it tetanus toxoid-stimulated T-cell proliferation at anti-human immunodeficiency virus type 1 concentrations.
Attachment of human immunodeficiency virus type 1 (HIV-
1) to CD41 target cells is mediated through binding of the viral
envelope glycoprotein gp120 to the CD4 receptor (9, 15). We
have identified a class of compounds that effectively block
gp120 binding to CD4 and suppress HIV-1 infection in vitro.
The compounds are condensation products of 2-naphthalene
sulfonic acid and formaldehyde and have the general structure
shown in Fig. 1. In this study, we evaluated the biochemical and
antiviral properties of a crude preparation (PIC 024-4, which
contains polymers of various sizes) and of a better-defined
fraction in which 60% of the polymers had molecular masses of
5 6 1 kDa (PRO 2000).
PIC 024-4 and PRO 2000 inhibited the binding of recombi-
nant gp120 (IIIB isolate) to recombinant CD4 in an enzyme-
linked immunosorbent assay (ELISA) format in which bound
gp120 was detected by an envelope-specific monoclonal anti-
body coupled to horseradish peroxidase (HIV gp120/CD4 Re-
ceptor EIA kit; DuPont-NEN, Boston, Mass.). Fifty percent
inhibitory concentrations (IC50s) were 0.3 and 0.4 mg/ml, re-
spectively. Aurintricarboxylic acid, which has been reported to
inhibit the binding of gp120 to CD4 (7, 8), had an IC50 of '1
mg/ml. By contrast, an 8-kDa preparation of dextran sulfate,
which has been evaluated as an anti-HIV-1 agent in humans
and found to be inactive (11), was inactive in the ELISA. Both
PIC 024-4 and PRO 2000 showed much less effect on the
CD2-CD58 binding interaction, giving respective IC50s of 71
and 115 mg/ml in a similar ELISA format (1). This suggests
that the polymers selectively block the gp120-CD4 interaction.
Fluorescence quenching experiments provided direct evi-
dence that PIC 024-4 and PRO 2000 bind to CD4 in phos-
phate-buffered saline (Fig. 2). Addition of CD4 quenched the
intrinsic fluorescence in a saturable manner, indicating that the
naphthalene sulfonate units of the polymer bind directly to the
protein. An excitation wavelength of 315 nm ensured that no
inner filter effect or fluorescence signal was contributed by the
added protein. Furthermore, the low concentrations of both
reagents excluded significant collisional fluorescence quench-
ing. A nonlinear curve fit to a simple biomolecular binding
model (21) predicted an apparent dissociation constant of'20
nM and a stoichiometry of '1:1.
The HIV-1-inhibitory activities of PIC 024-4 were evaluated
in H9 CD41 lymphoblastoid cell lines, peripheral blood mono-
nuclear cells (PBMC), and primary monocyte/macrophages,
using assays that we have described previously (14). Cell via-
bility was assessed by trypan blue dye exclusion, and virus
replication was measured by detection of HIV-1 p24 antigen in
culture supernatant fluids (13). Several different HIV-1 iso-
lates were used, including 14aPre (14), N70 (6), IIIB (20), and
Ba-L (12). The IC50s and other inhibitory endpoint values were
determined by the dose-effect analysis described by Chou,
Chou, and Talalay (3–5).
Table 1 shows IC50s and IC90s, as well as toxic concentra-
tions, of PIC 024-4 and PRO 2000 against various HIV-1 iso-
lates. PIC 024-4 and PRO 2000 inhibited infection by a wide
range of HIV-1 isolates in a variety of cell types, including a
CD41 cell line (H9), PBMC and monocyte/macrophages. In
separate studies (19a), PIC 024-4 suppressed infection of
PBMC by the clinical isolate JR-CSF and suppressed infection
of macrophages by the monocytotropic isolate ADA. IC50s
were similar to those reported here. This activity profile ap-
pears to differ from that of dextran sulfate, which has been
reported to be inactive against several macrophage-tropic iso-
lates, including Ba-L (17). Although toxicity was not observed
up to day 4 in culture, it appeared between days 4 and 11, as
assessed by cell viability and proliferative capacity.
Since PIC 024-4 and PRO 2000 showed time-dependent
cytotoxicities in vitro, experiments were conducted with PRO
2000 in H9 cells to determine the minimal duration and con-
centration required to achieve an antiviral effect and circum-
vent toxicity. Limited exposure to a concentration of 100, 40,
20, or 10 mg/ml administered once and followed by either drug
removal after 3 days or postwash maintenance in low drug
concentrations (1 mg/ml) was effective in suppressing p24 an-
tigen production following acute infection as well as in circum-
venting toxicity. Complete inhibition was observed with PRO
2000 at 100 mg/ml; there was no viral breakthrough seen over
28 days in culture (Fig. 3). Partial inhibition occured at con-
centrations of 10 to 40 mg/ml. No toxicity was observed at
concentrations of #100 mg/ml to day 28 after these limited
exposures. In the case of established infection, however, in
which cells were exposed to the virus 4 h prior to the addition
of PRO 2000, there was only transient suppression of viral
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replication to day 7, and viral breakthrough was observed by
day 11 (data not shown).
Limited exposure to PRO 2000 was also evaluated in PBMC.
No toxicity was observed with up to 50 mg/ml with 24-h expo-
sures, and the IC50 and IC90 with HIV-1 14aPre were 12.8 and
30.3 mg/ml, respectively.
HIV-1 was passaged in the presence of increasing concen-
trations of PIC 024-4 (3 to 12 mg/ml) over a 212-day culture
period. Higher concentrations of the compound could not be
used because of toxicity. Decreased susceptibility of passaged
virus did not develop under these conditions.
We also evaluated combinations of PIC 024-4 or PRO 2000
with zidovudine against HIV-1 14aPre by using techniques pre-
viously described (14). Antiviral synergy was observed between
PIC 024-4 and zidovudine at the IC75, IC90, and IC95 (combi-
nation indices of 0.7, 0.4, and 0.2, respectively); synergy be-
tween PRO 2000 and zidovudine occured at the IC90 and IC95
(combination indices of 0.8 and 0.8). No toxicity was ob-
served at the concentrations tested over the 4-day assay period.
Since the CD4 receptor plays a role in the normal immune
response by interacting with the T-cell receptor–HLA class
II–antigen complex during T-cell activation, PIC 024-4 and
PRO 2000 were evaluated for their effects on tetanus toxoid-
induced stimulation of PBMC from normal tetanus toxoid
responders. Stimulation, as measured by [3H]thymidine incor-
poration after 5 days in culture, was unaffected by concentra-
tions of up to 50 mg/ml, which is well above the average IC50
for antiviral activity (data not shown).
Several organic compounds, including a series of naphtha-
lene disulfonates, have been reported to suppress HIV-1 in-
fection by disrupting the gp120-CD4 binding interaction (10,
18, 19). Recent data suggest that many of these compounds
may not disrupt gp120-CD4 binding but rather may affect the
cationic V3 loop of gp120, which appears to mediate a post-
binding fusion event (2, 16). Although they are structurally
related to other anionic compounds that suppress HIV-1 in-
fection, the naphthalene sulfonic acid polymers PIC 024-4 and
PRO 2000 show distinct antiviral and biochemical properties in
vitro. In contrast to dextran sulfate and the low-molecular-
weight naphthalene disulfonates, the polymers effectively block
the gp120-CD4 binding interaction and bind tightly to recom-
binant CD4 under physiological conditions. Additional antivi-
ral mechanisms, including interference with CD4-mediated
postbinding events or interactions with gp120, cannot yet be
excluded.
The activity of the naphthalene sulfonate polymers in vivo
may be affected by pharmacokinetics, binding to serum com-
ponents, or the ability to reach sites of viral replication. In
addition, toxicity may be a problem with these compounds with
prolonged use. Although toxicity was not observed at thera-
peutic drug concentrations up to day 4 in culture, it was ap-
parent between days 4 and 11, thereby narrowing the thera-
peutic effect/toxic effect ratios after prolonged exposure. This
effect could be overcome by limiting the time of cell exposure
to either drug. If drugs were removed after 24 to 72 h, antiviral
effects persisted and toxicity was minimized. Whether less-
frequent dosing will be necessary in vivo remains to be deter-
mined.
Multiple-dose toxicity studies of PRO 2000 in rodents and
FIG. 1. General structure of PIC 024-4 and PRO 2000. Methylene bridges
may connect different ring positions. For PRO 2000, n ' 20.
FIG. 2. Fluorescence emission spectrum of PRO 2000 in the absence and
presence of recombinant soluble CD4 (sCD4) (domains 1 and 2). (Inset) Frac-
tion of PRO 2000 bound as a function of recombinant soluble CD4 concentra-
tion. Kd, apparent dissociation constant.
TABLE 1. IC50s, IC90s, and toxicities of PIC 024-4 and PRO 2000 against HIV-1
Drug and






Prolonged exposurea Limited exposureb
PIC 024-4
3 H9 IIIB 0.4–0.7 0.7–1.4 .15 NDc
1 H9 14aPre 1.3 4.9 .15 ND
5 PBMC 14aPre 8.4–14.3 17.9–29.2 .12 ND
1 PBMC N70 3.9 12.8 .12 ND
1 Monocyte/macrophage Ba-L 1.2 4.5 .16.7 ND
PRO 2000
2 H9 IIIB 0.7–1.0 ND .5 .100
1 PBMC 14aPre 12.8d 30.3d .5 .50
a Toxicity was observed between 4 and 11 days in culture.
b Drug was removed from culture after 24 to 72 h of exposure.
c ND, not determined.
d PRO 2000 activity against HIV-1 was evaluated by limited drug exposure of 24 h.
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cynomolgus monkeys have shown that the most sensitive end-
points for high-dose effects are prolongation of activated par-
tial thromboplastin time and elevation of alanine aminotrans-
ferase levels (20a). In vitro, the concentration of PRO 2000 in
citrated human plasma required to double the activated partial
thromboplastin time is 10-fold greater than the corresponding
concentration of dextran sulfate (8 kDa), suggesting that the
higher doses of PRO 2000 can be safely administered. In mice,
total T-cell levels, T-cell subset ratios, and T-cell mitogenic
responses to concanavalin A were largely unaffected by PRO
2000 administration (20a). Details of these studies will be re-
ported elsewhere. Clinical testing of PRO 2000 in humans is
now under way.
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FIG. 3. Inhibition of HIV-1 replication by limited exposure (3 days) to PRO
2000 at 10 ({), 20 (E), 40 (), or 100 (µ) mg/ml following simultaneous infection
of H9 cells.h, infected control. For the 40-mg/ml preparation, one of two culture
wells showed viral breakthrough by day 18, and the second culture well showed
suppression of virus through day 28 in culture.
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